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Abstract: Background: In the UK, treatment recommendations for patients with cancer are
routinely made by multidisciplinary teams in weekly meetings. However, their
performance is variable.
Objective: To explore the underlying structure of multidisciplinary decision-making
process, and examine how it relates to team ability to reach a decision.
Design, Settings and Participants: A cross-sectional observational study consisting of
1,045 patient reviews across four multidisciplinary cancer teams from teaching and
community hospitals in London, UK from 2010 to 2014. Meetings were chaired by
surgeons.
Measurements: We used a validated observational instrument (Metric for the
Observation of Decision-making in Cancer Multidisciplinary Meetings) consisting of 13
items to assess the decision-making process of each patient discussion. Rated on a
five-point scale, the items measured quality of presented patient information, and
contributions to review by individual disciplines. A dichotomous outcome (yes/no)
measured team ability to reach a decision. Ratings were submitted to Exploratory
Factor Analysis and regression analysis.
Results: The exploratory factor analysis produced four factors, labelled 'Holistic and
Clinical inputs' (patient views, psychosocial aspects, patient history, comorbidities,
oncologists', nurses', and surgeons' inputs), 'Radiology' (radiology results, radiologists'
inputs), 'Pathology' (pathology results, pathologists' inputs), and 'Meeting Management'
(meeting chairs' and coordinators' inputs). A negative cross-loading was observed from
surgeons' input on the fourth factor with a follow-up analysis showing negative
correlation (r = -0.19, p < 0.001). In logistic regression, all four factors predicted team
ability to reach a decision (p < 0.001).
Limitations: Hawthorne effect is the main limitation of the study.
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Conclusions: The decision-making process in cancer meetings is driven by four
underlying factors representing the complete patient profile and contributions to case
review by all core disciplines. Evidence of dual-task interference was observed in
relation to the meeting chairs' input and their corresponding surgical input into case
reviews.
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 London April 25th 2016 
Dear Professor Wall,  
Thank you for your detailed and positive evaluation of our manuscript, “The anatomy of clinical 
decision-making in multidisciplinary cancer meetings: a cross- sectional observational study of teams 
in a natural context” (MD-D-16-01188), and the decision to invite a revised version in accordance with 
the comments of the reviewers. 
In what follows, we have summarized the points raised by the reviewers (in italics), and have described 
our response to them and the relevant amendments to the manuscript. All changes to the manuscript are 
highlighted in red font. 
 
Reviewer #1 
I really appreciate the opportunity to review the Manuscript # MD-D-16-01188 entitled: 
"The anatomy of clinical decision-making in multidisciplinary cancer meetings: a cross-sectional 
observational study of teams in a natural context". I commend the authors for describing this important 
and timely issue. The paper is very interesting and well written, and as reviewer I have no issues to 
highlight. Very good. 
Thank you for the very positive reception of our study.  
 
Reviewer #2 
The submitted manuscript describes an interesting observational study on the topic of health care 
decisions within multidisciplinary care teams. The four factors discovered in this study are meaningful 
and informative in clinical decisions for cancer patients. Overall, this manuscript is of high quality but 
some concerns needed to be addressed before it is accepted for publication. 
1) The biggest concern is the study design. The reviewer may miss the information, but the basic setup 
is one or two clinicians are serving as observers in each meeting. Do other team member aware of who 
the observer is or whether they’re being observed? Masking of such information will greatly reduce the 
Hawthorne effect. But it is not clearly stated. 
This is a fair point, requiring clarification as requested. All observational research has the potential to 
suffer from the Hawthorne effect whereby the behavior of those being observed is affected by process 
of observation. We have acknowledged this in the limitations. All participants gave informed consent 
OA_Response to Reviewers
 to the observation of their MDT meeting. They were briefed on the nature of the study and the type of 
data that was being collected, therefore they were aware that they were going to be observed. However, 
MDTs in the UK rarely have the exact same composition every week as members have other 
commitments, might be on leave, etc. They are commonly attended by visiting clinicians, students, 
researchers, clinical auditors as well as interns and residents on rotation. This means that in practice 
being ‘observed’ in some way or other is rather common within these teams – and hence the presence 
of our study’s clinical observers did not in itself introduce an overwhelming bias. We therefore believe 
that the presence of the observer, discreetly positioned at the back of the MDT meeting, would have 
had minimal impact on the proceedings of the meetings, particularly as the study occurred over a 
number of meetings (and thus allowed for acclimatization of the teams to the observers), and the 
observer was a clinician (specialized in the cancer that they observed), the presence of whom within the 
MDT is natural. The manuscript has been adjusted to clarify this element (please see pages 6 and 9) – 
although the overall methodological limitation remains and has been fully acknowledged.  
 
2) The medical decisions made by the same team are correlated even if we eliminate the effect of 
cancer type. In reality, some surgeons or clinicians or radiologists may prefer one type of 
care/procedure due to personal training background, availability of instruments or the financial 
situations of patients. As a result, the decisions made for different cases by one team are highly 
correlated. In this sense, traditional logistic regression fails because it assumes independent 
(uncorrelated) outcome measures. It’s highly recommended to use mixed effects modeling or 
hierarchical modeling to address the correlation issue. 
This is a well-made point and an established limitation of the regression approach we took. We sought 
further advice from a statistician on this – and based on the datasets that we have the modeling 
suggested here would not be suitable. This is due to the relatively small number of specialists within 
the study – in relation to the number of cases analyzed – which would not have allowed the type of 
analyses suggested. We were thus advised to report the regression and acknowledge the lack of ability 
within the study to further explore this potential lack of independence – we have fully complied with 
this and discussed this issue accordingly (please see pages 9-10). 
Having reflected further on this comment, we would suggest that this is a worthwhile hypothesis for 
further testing – i.e. are the decisions independent or not, and if not what are the factors that drive these 
conscious or unconscious preferences as expressed at the MDT? We have included this reflection 
within the discussion as well (please see pages 9-10).  
 
 3) The last sentence right before the discussion is intriguing. Do authors use probability of 0.5 as a 
cutoff for predicted yes/no decision?  
We used probability of 0.05 as a cutoff for predicted yes/no decision. This is clarified at the end of the 
Methods/Statistical Methods section (please see page 6). 
 
What’s more, the performance of a model should not be evaluated based on the data it was built. 
Instead, a new set of data should be used to assess the predictive power of the final model. Authors are 
recommended to conduct more studies for this conclusion.  
This is a very good point which has mistakenly been overlooked in the reporting of our study – thank 
you for pointing it out. We fully agree, and the last sentence right before the discussion on page 9 has 
now been removed. More studies will be conducted in the future to assess the predictive power of our 
model on different datasets that we are compiling.  
 
Please also submit high-quality graphs for Figure 1 and Figure 2.  
This has been addressed in the revised manuscript.  
 
Reviewer #3  
This manuscript aimed to explore the underlying structure of multidisciplinary decision-making 
process, and examine how it relates to team ability to reach a decision. The manuscript is overall well-
written, but there are issues that need to be addressed. The authors need to provide more details of the 
instrument, especially the scoring and their functions.  
In the current manuscript, there is no indication as to how the authors implemented the tool that 
involve subjective scoring (did one author perform, or all, how were variations handled, etc). 
- Please clarify whether training in the instrument is required to judge readability. 
- It seems that in each independent cancer team, there is one of the authors in charge of the scoring. 
- There is no inter-rater reliability on any of the items utilized. 
 
Thank you for these points, which all required clarification. In summary:   
-Training in the use of the instrument is required in order to be able to use it consistently. The surgeon 
evaluators had all been trained to use the instrument prior to the study (as part of our wider research 
and clinical improvement program for cancer teams).  
 -Within each cancer team one of the authors conducted observations and scoring because that cancer 
team corresponded to their clinical specialty. Reliability in the scoring was assessed for each one of the 
surgeon evaluators via correlating their scoring with the scoring of a paired blinded assessor (i.e. one of 
the other surgeons in the team).  
Both of these points have been addressed in the manuscript (please see pages 6 and 4, respectively). 
- In terms of the inter-rater reliability - we included the aggregated data on this measure within the 
results to avoid an overload of technical information for the readership. Reporting all individual items 
inevitably results in a long table. To address this point we have now included the full reliability 
analyses as a supplementary data table (please see page 7). 
 
Please show the heterogeneity of the actual data (not only the numbers or the results of exploratory 
factor analysis) is the important factor for readers to appreciate. 
This is a good point, and we entirely agree that readers will find these data useful. We have now 
included a full table with descriptives across all MDT-MODe items and tumour types (see page 7 and 
Table 2 in the revised manuscript).  
 
On page 5, “It allows the evaluator to rate the following variables in vivo on a five-point scale” 
What does it mean by “in vivo”? 
This has been changed into “in real-time” in the manuscript (see page 5) meaning live (as opposed to 
retrospective based on video recordings for example). 
 
In the term “Exploratory Factor Analysis”, initial letters do not need to be all capitalized. 
Please correct “P < .001” as “p < 0.001” also, “p < .01” should be “p < 0.01”. 
Figure 1 is not clear enough to read. 
These points have been addressed in the revised manuscript (see pages 2, and 6-8).  
 
In Table 1, the authors present “No. of cases with a decision reached (%)”. What about those “cases 
without a decision reached”? What are the main reasons for failing to make a decision? 
This is a very good point and one that we regret not being able to explore in more detail within each of 
the four tumor groups since it was beyond the scope of our study. Ethical approvals for the original 
work in the breast, lung and colorectal teams precluded recording anything other than the behavioral 
 scoring of the team (i.e., MDT-MODe), and so detailed information on the reasons for failing to make a 
decision is unobtainable for these teams. However, the urology dataset did indeed look into this - Lamb 
et al (2013) revealed that the top 3 causes of decision failures were inadequate radiologic (39.3% 
decisions) and pathological (26.0%) information, as well as inappropriate patient referrals (10.7%). We 
suspect this may also be the case for other teams, however, we cannot confirm this across all the tumors 
within our dataset, and hence we have not reported this information. 
 
Table 3 is so simple that it does not provide any meaningful results. Thus, it’s hard to interpret. 
Table 3, representing correlation matrix between extracted factors, has been removed from the 
manuscript. 
 
On page 8, the authors state that in the multiple logistic regression analysis, “after adjusting for tumor 
type, all four factors were significantly related to the treatment decision”, and “The regression model 
accurately predicted 920 out of 1045 treatment decisions with a high prediction accuracy of 88%.” Did 
the authors use original scores in the regression model?  
Original scores were used in the regression model, and as per Reviewer #2 comments – “the 
performance of a model should not be evaluated based on the data it was built. Instead, a new set of 
data should be used to assess the predictive power of the final model. Authors are recommended to 
conduct more studies for this conclusion”, the sentence “The regression model accurately predicted 
920 out of 1045 treatment decisions with a high prediction accuracy of 88%.” has been removed from 
the manuscript, and more studies will be conducted in the future to assess the predictive power of our 
model (see pages 8-9). 
 
Also, how did the authors define “high prediction accuracy”? 
As per the above answer, this sentence has been removed from the manuscript. 
 
How did the authors define “treatment decision” as variables in the model?  
Variable “treatment decision” was defined as a categorical outcome variable with 0 indicating no 
decision reached, and 1 decision reached by the MDT. Table 4 and page 6 have been adjusted to reflect 
this. 
 
 We would like to thank again the editorial team and the reviewers for these insightful comments that 
helped us clarify the manuscript and significantly improve how we reported our findings. We do hope 
that, following these revisions, the manuscript is now acceptable for publication in Medicine.  
Kind regards 
Ms Tayana Soukup 
(on behalf of all authors) 
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Abstract  
Background: In the UK, treatment recommendations for patients with cancer are routinely made by 
multidisciplinary teams in weekly meetings. However, their performance is variable.  
Objective: To explore the underlying structure of multidisciplinary decision-making process, and 
examine how it relates to team ability to reach a decision.  
Design, Settings and Participants: A cross-sectional observational study consisting of 1,045 patient 
reviews across four multidisciplinary cancer teams from teaching and community hospitals in London, 
UK from 2010 to 2014. Meetings were chaired by surgeons.  
Measurements: We used a validated observational instrument (Metric for the Observation of Decision-
making in Cancer Multidisciplinary Meetings) consisting of 13 items to assess the decision-making 
process of each patient discussion. Rated on a five-point scale, the items measured quality of presented 
patient information, and contributions to review by individual disciplines. A dichotomous outcome 
(yes/no) measured team ability to reach a decision. Ratings were submitted to Exploratory Factor 
Analysis and regression analysis.  
Results: The exploratory factor analysis produced four factors, labelled ‘Holistic and Clinical inputs’ 
(patient views, psychosocial aspects, patient history, comorbidities, oncologists’, nurses’, and 
surgeons’ inputs), ‘Radiology’ (radiology results, radiologists’ inputs), ‘Pathology’ (pathology results, 
pathologists’ inputs), and ‘Meeting Management’ (meeting chairs’ and coordinators’ inputs). A 
negative cross-loading was observed from surgeons’ input on the fourth factor with a follow-up 
analysis showing negative correlation (r = -0.19, p < 0.001). In logistic regression, all four factors 
predicted team ability to reach a decision (p < 0.001).  
Limitations: Hawthorne effect is the main limitation of the study.  
Conclusions: The decision-making process in cancer meetings is driven by four underlying factors 
representing the complete patient profile and contributions to case review by all core disciplines. 
Evidence of dual-task interference was observed in relation to the meeting chairs’ input and their 
corresponding surgical input into case reviews.  
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Introduction 
Background 
As a mandatory part of cancer care services in the UK, multidisciplinary team meetings (MDM) 
comprise of diverse range of professionals – including surgeons, oncologists, radiologists, specialist 
cancer nurses and pathologists [1]. Their purpose is to provide expert reviews of patient cases and 
formulate treatment recommendations, thus improving patient experience and ensuring well-
coordinated delivery of safe, high quality care. Although cancer guidelines support a multidisciplinary 
approach [1], the empirical evidence of its effectiveness in terms of patient survival remains unclear 
[2], and team performance across tumors is variable [3]. One pattern that keeps re-emerging in recent 
studies is the skewed contribution to case reviews towards senior physicians and biomedical aspects of 
the disease; in contrast, cancer nurses’ input, patients’ comorbidities, and their psychosocial 
circumstances are underrepresented [4-6]. In line with this pattern, evidence from patient experience 
studies shows suboptimal experience of care often due to psychosocial circumstances not being 
adequately addressed and a ‘holistic’ view of the patient not being considered by the healthcare 
providers [7-8]. Moreover, multidisciplinary team (MDT) members highlighted the importance of 
having a complete patient profile, as well as all participating disciplines in attendance, for effective 
decision-making [9]. Improving MDT working therefore is complex although highly important with 
the cancer incidence and costs of care being predicted to rise [10-11], while the significant financial 
pressures on the healthcare remain [12].  
The National Cancer Action Team in England identified core domains essential for effective MDT 
working, including the team (e.g. attendance, team culture, training), infrastructure for meetings, 
organisation and logistics, team governance, and finally, clinical decision-making process [13] – the 
latter being the primary focus of this paper. Time pressures, cancer specialist non-attendance, lack of 
necessary information, poor consideration of patient wishes and comorbidities [9], as well as poor 
team climate [14] have all been reported to have negative impact on the team in MDMs. 
Correspondingly, the functional perspective of group decision-making posits that the internal factors 
coming from within the group  (member composition, group size, interactions, culture, beliefs, 
attitudes, history among group members), and the external circumstances (time pressure, workload) 
both impact the way groups perform, with the group size and diversity being positively related to 
performance and range of abilities, and negatively related to effective processes and equality of 
participation [15-16]. This pattern is also evident in cancer MDMs.  
More research is therefore needed to understand how the process of decision-making is currently 
structured in MDMs - whether this is at the service of promoting effective decision-making, and how 
it impacts team outcomes. For instance, evidence from MDMs shows that the chairing of the meeting 
tends to be led by one of the contributing disciplines, and predominantly by more senior surgical 
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members of the team [17]. This, however, may not be an optimal set up. Evidence from cognitive 
psychology shows that the competition in dual-task performance (in the case of the MDM, chairing 
whilst contributing to case reviews) is detrimental to one or both tasks that are being undertaken 
simultaneously [18], while evidence from patient safety and functional perspective shows that 
communication between healthcare professionals can be negatively affected by a steep authority 
gradient, which can emerge when a senior clinician chairs a MDM [15,19-22]. The latter finding is 
further supported by early social science research [23-24], the results of which were subsequently used 
to improve team effectiveness in many industries, including aviation [25].  
Objectives 
Our primary objectives were to 1) examine the underlying structure of team decision-making during 
case reviews, investigating how the different elements of the decision process cluster together, and 2) 
understand how it affects team outcome, i.e., the team ability to reach a treatment decision/plan.  
 
To achieve this, we conducted a series of analyses on a large multi-tumor database that was compiled 
using a novel validated instrument for the observational assessment of decision-making in cancer 
MDMs - namely, Metric for the Observation of Decision-Making in cancer MDTs, also known as, 
MDT-MODe [4]. Although tools have been developed to evaluate various aspects of MDM 
performance, to our knowledge, this is the only instrument designed specifically to measure the 
process of multidisciplinary decision-making.  
Methods 
Study Design 
This is a cross-sectional observational study that represents a secondary analysis of the data. 
Originally, the data were acquired through our centre’s ongoing research program in evaluating and 
improving MDT working across different tumors and was used to descriptively assess decision-
making process within cancer teams using MDT-MODe. Since this was a secondary analysis, ethical 
approval was not required, however at the time of data collection ethical approvals were in place for 
all prospective evaluations.  
Setting 
The study recruited four independent cancer teams between 2010 and 2014 from one teaching 
university hospital (lung cancer team) and three large community hospitals (breast, colorectal and 
urology cancer teams) of the London (UK) metropolitan area. Observations were conducted in real-
time over 10 consecutive meetings within each MDT by four trained surgeon evaluators (breast=SA, 
colorectal=SMS, lung=SS, urological=BWL) who assessed the cancer team that corresponded to their 
clinical specialty. Reliability was assessed by having four surgeon evaluators score a subset of cases in 
pairs. The evaluators were not members of the MDT they were assessing.  
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Participants and Study Size 
Participants were 4 multidisciplinary cancer teams with a total of 52 members, and an overall of 1,045 
individual case reviews discussed over a period of 10 weekly meetings respectively. Eligibility criteria 
for the study were defined as multidisciplinary cancer teams from the UK National Health Service 
(NHS) that represent four most common types of cancer (breast, lung urological and colorectal) and 
discuss patients referred to them for care planning recommendations. An availability sampling 
approach was used to identify teams that met eligibility criteria, while a set number of meetings within 
each team determined the number of case discussions for analysis.  
Variables and Measurements  
Case reviews within each meeting and across all four cancer teams were assessed in the same manner 
by assessors who were clinicians specialised in the cancer they observed, and trained beforehand in 
the use of the MDT-MODe, a quantitative observational assessment tool (Figure 1) [4]. Training in the 
use of the tool is essential in order to be able to use it – this is a general principle for instruments 
assessing human factors in clinical environments, such that the evaluations produced have a degree of 
accuracy and can be meaningfully used [29]. The tool has been validated, and previously used to 
assess various cancer MDTs [e.g. 26-28]. The instrument allows a trained evaluator (using the form 
shown in Figure 1) to provide for each case review carried out by the MDT a standardized score on a 
1-5 behaviorally anchored scale of the following variables in real-time: 
(i) Quality of information presented at the MDM as measured by six variables, namely, 
patient history, radiology results, pathology results, patient psychosocial aspects (i.e. 
psychological and social factors, including mental health difficulties, socio-economic issues, 
and personal circumstances), comorbidity (i.e., past medical history and performance status), 
and patients’ wishes or opinions regarding treatment. 
(ii) Quality of multidisciplinary case review as measured by the contributions of seven core 
disciplines, namely, chairperson, surgeon, oncologist, nurse, radiologist, histopathologist and 
coordinator. Quality of MDT chairing is evaluated based on national guidelines for England 
[13], which outline the core competencies that are important for chairing: meeting 
management, listening and communication, interpersonal relations, managing disruptive 
personalities and conflict, negotiations, facilitating effective consensual decision-making and 
time management. Other MDT-members are rated on the basis of their clear contribution of 
their specialty to the case review.  
The outcome measure is a dichotomous variable (yes/no) that allows recording whether or not a clear 
treatment decision was reached for a patient (Figure 1). In the statistical analysis, type of tumor was 
considered as a potential confounder. No other variables were included in the final model.  
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----------------------- 
Figure 1 
---------------------- 
Bias 
Efforts were made to address potential biases in the study. We addressed observer bias and had 
ensured reliability of evaluations on the MDT-MODe by having a subset of cases scored by the four 
clinical evaluators in pairs who were all trained and experienced in the use of the instrument. During 
data collection, each evaluator was blind to the other evaluators’ observations. All data were collated 
for analysis by a separate researcher (TS). We are aware that Hawthorne effect, i.e., teams changing 
their usual behavior due to being observed, is a natural limitation to observational studies, and in our 
study MDT members were aware that they were being observed. In England, MDMs are commonly 
attended by visiting clinicians, students, researchers, clinical auditors as well as interns and residents 
on rotation. This means that in practice being ‘observed’ in some way or other is rather common 
within these teams – and hence the presence of our study’s clinical observers would not be 
overwhelming to the teams. We therefore believe that the presence of the observer, discreetly 
positioned at the back of the MDT meeting, would have had minimal impact on the proceedings of the 
meetings, particularly as the study occurred over a number of weeks (and thus allowed for 
acclimatization of the teams to the observers), and the evaluators were clinicians (specialized in the 
cancer that they observed), the presence of whom within the MDT is natural. We return to the 
Hawthorne effect issue in the discussion.   
Statistical Methods 
Intra-class coefficient (ICC) analysis was initially used to assess reliability of evaluations. ICCs can 
range between 0 and 1, with higher values indicating better agreement between evaluators. A recent 
expert consensus has defined a reliability coefficient of 0.70 as a minimum value for data to be used 
for research purposes [29].  
Exploratory factor analysis (EFA) and logistic regression were subsequently carried out to assess the 
underlying structure of decision-making process during case reviews. The variables that were included 
in the EFA were individual items of information and specialist contribution quality as assessed by 
MDT-MODe. EFA extracted factors (using a regression method) were then entered in a multiple 
logistic regression model as predictor variables to assess their relation to the outcome, i.e., team ability 
to reach a decision with 0 denoting no decision reached, and 1 decision reached. Variable representing 
individual teams within the sample (i.e., breast, lung, urology and colorectal cancer teams) was also 
entered in the regression model as a covariate to examine its’ potential confounding effect. 
Significance was set at p < 0.05. 
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All analyses were carried out using SPSS® version 20.0 software, and there were no missing data.  
Results 
Descriptive Analysis 
The descriptive data for meeting characteristics are shown in Table 1. Representing the most common 
cancers in the UK, the sample consisted of overall 1,045 case discussions across 4 teams within a NHS 
setting. The composition of health care personnel in MDTs did not significantly vary across groups. 
All teams consisted of a coordinator (administrator), chair and senior (Consultant/Attending level) 
cancer specialists, i.e., surgeons, oncologists, radiologists, pathologists, and cancer nurses, with the 
exception of lung, where a chest physician was also present. Table 2 shows detailed descriptive data 
for the MDT-MODe variables across all four cancer teams. 
------------------------------ 
Tables 1 & 2 
------------------------------ 
Reliability of Evaluations: Intra-class correlation coefficients (ICCs)     
Inter-evaluator agreement was assessed via ICCs on a randomly selected subset of the observed cases 
(N=273, 26% of the total cohort). High reliability was obtained across all tumors; breast: median 
ICC=0.92 (range 0.27-1.00); colorectal: median ICC=0.83 (range 0.69-0.96); lung: median ICC=0.86 
(range 0.71-0.99); and urological: median ICC=0.71 (range 0.31-0.87). This finding means that all 
four surgeon evaluators were consistent in their use of the MDT-MODe instrument across evaluated 
cases. The full intrarater reliability matrix for all individual items across all four cancer teams is 
provided as the Supplementary data table. 
Anatomy of Decision-Making: Exploratory Factor Analysis (EFA) 
To assess the underlying structure of the decision-making process in MDM, an EFA was applied to the 
13 MDT-MODe items. All the criteria for factor analysis were met – sample size was adequate (KMO 
= 0.67), and the variables sufficiently intercorrelated, (𝑋2(78) = 3329.18, p < 0.001), with none of the 
coefficients being particularly large or zero. Based on (i) Kaiser’s criterion (eigenvalues for the first 
six factors were 2.99, 2.11, 1.34, 1.19, 0.95, 0.89), (ii) Scree plot and (iii) clinical considerations, 4 
factors were extracted and rotated to simple structure via the oblique Promax algorithm with the 
Kappa parameter set to 4. Oblique rotation was chosen because it is considered a more accurate, 
reproducible solution, allowing the factors to correlate [30]. The four factors together explained 59% 
of the variance in the 13 MDT-MODe items. All items were well represented in the extracted four 
factors, with an average communality of 0.59. The best represented items were radiologists’ input, ℎ2 
= 0.84, pathologists’ input, ℎ2 = 0.83, radiological information, ℎ2 = 0.83, and pathological 
information, ℎ2 = 0.84, while the least well represented item was chair’s input ℎ2 = 0.39. 
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Table 3 presents the resulting factor pattern matrix. The highest-loading variables on the first factor 
were patient views on the treatment options (0.70), oncologists’ input into case discussion (0.67), 
nurses’ input into case discussion (0.65), and patient psychosocial aspects (0.60).  Accordingly, this 
factor was labelled ‘Holistic and Clinical inputs’, representing patients’ holistic and clinical needs. 
The highest-loading variables on the second factor were patient radiological information presented to 
the team (0.91) and radiologists’ input into case discussion (0.93).  Accordingly, this factor was 
labelled ‘Radiology’, representing radiological profile of patients’ disease. The highest-loading 
variables on the third factor were patient pathological information presented to the team (0.90) and 
pathologists’ input into case discussion (0.96). Accordingly, this factor was labelled ‘Pathology’, 
representing pathological profile of patients’ disease. The highest-loading variables on the fourth 
factor were coordinator’s (0.68) and meeting chair’s (0.61) inputs into case discussion. Accordingly, 
this factor was labelled ‘Meeting Management’, representing the management of case discussions 
within the meeting (chair), and general management and organisation of cases for discussion 
(coordinator). Figure 2 shows a graphical representation of the four-factor model. 
 
.------------------------------ 
Table 3 & Figure 2 
------------------------------ 
As evident from Table 3, one variable, namely, surgeons’ input, cross-loads positively (0.43) on 
‘Holistic and Clinical inputs’, and negatively (-0.41) on ‘Meeting Management’. Since surgeons in our 
sample also chaired the meetings, thus undertaking two tasks simultaneously, we further explored the 
relationship between the two using Spearman correlational analysis. A significant negative association 
was found between surgeons’ and chairs’ inputs to case reviews (r = -0.19, p < 0.01), indicating that as 
the surgeons’ inputs increased, the chairs’ inputs decreased. In contrast, the relationship between 
surgeons’ and coordinators’ inputs was non-significant (r = -0.04, p > 0.05). It is reasonable to 
conclude, therefore, that the negative cross-loading in the EFA is driven by the negative surgeon-chair 
association. This finding is in line with the theory of dual task interference [18], as discussed later. 
Factor inter-correlations were generally low at r = 0.26 or less. The full factor inter-correlation matrix 
is available upon request from the corresponding author. 
Predictors of Outcome: Logistic Regression 
To explore the relation between the four factors and the outcome variable, namely, the team ability to 
reach a treatment decision on first case review, we performed a multiple logistic regression analysis. 
After adjusting for tumor type, all four factors, including ‘Holistic and Clinical inputs’ (Wald(1) = 
17.88, p  < 0.001), ‘Radiology’ (Wald(1) = 12.01, p < 0.001), ‘Pathology’ (Wald(1) = 23.22, p  < 
0.001), and ‘Meeting Management’ (Wald(1) = 12.30, p < 0.001) were significantly related to the 
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treatment decision. To facilitate interpretation, we converted the odds ratios into probability 
percentages, using the following formula: odds/(odds+1) x 100 = probability % [31]. We found that 
‘Holistic and Clinical’ inputs, ‘Radiology’ and ‘Pathology’ contributed the most to the probability of 
the team to reach a treatment decision for a patient (see Table 4).  
----------------------------- 
Table 4  
------------------------------ 
Discussion  
Summary 
The current study used multivariate statistical methods to gain a better understanding of the anatomy 
of group decision-making in cancer MDMs, and how it relates to team ability to reach treatment 
recommendation. We showed that the decision-making process in cancer MDMs is driven by four 
underlying factors – namely, ‘Holistic and Clinical inputs’, ‘Pathology’, ‘Radiology’, and ‘Meeting 
Management’. These were all significantly predictive of team ability to reach a treatment decision on 
first case review. The inputs of chairs (who were surgeons in our sample) were shown to compete with 
their corresponding disciplinary contributions to case reviews at the detriment of the meeting 
management – i.e., as surgeons’ input to case reviews increased, chair’s input decreased.  
Limitations  
We have used observational data with participants being aware that they were being evaluated, hence 
we cannot rule out observer biases and the Hawthorne effect. This is a natural limitation to all 
observational evaluations, and in our dataset, we used blinded clinical evaluators (the presence of 
whom within a MDT is natural) and a previously validated tool, ensuring satisfactory inter-assessor 
reliability. Further, the nature of MDT-MODe may not do justice to the complex roles of the MDT 
chairperson and coordinator. This is being addressed via a more detailed evaluation scale we are 
currently constructing for chairing skills [33]. Although we have made an attempt to control for the 
confounding effects of tumor type, we acknowledge that our data are derived from different 
institutions and MDTs, and that team culture including different values, beliefs and attitudes could 
influence outcomes [16]. This may have affected institutional versus team-specific or tumor-specific 
factors impacting on team decision-making. In a similar vein, conscious or unconscious preferences 
for treatment may be embedded into individual specialists’ decision-making; ideally, these should also 
be factored into the decision-making ‘model’ of the MDM as they are likely to be a stable feature of 
each individual physician’s decision style. Our study was not designed to address all of these 
complexities, which would have rendered its scope unfeasible. Future work should therefore explore a 
large stratified sample of cases across hospitals and tumors to further validate our findings, and also 
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the intra-individual physician preferences for treatment options. Such research would offer further 
understanding of how these differences affect multidisciplinary decision-making process.  
Overall Interpretation 
Previous research has shown that clinical decision-making process is an essential part of effective 
MDT working [13]. Our findings build on this by showing that the decision-making process in MDMs 
is driven by four underlying factors representing all core disciplines and the complete patient profile - 
both essential for the teams’ ability to reach a decision. In a recent study, MDT members reported the 
importance of member attendance, availability of patient information, considerations of patient 
comorbidities, patient choices and their current state of health for decision-making [9]. Our paper 
corroborates this finding by showing that in order for the team to be able to reach a treatment 
recommendation on first case review, all participating disciplines and the complete patient profile are 
necessary. This is also in line with the functional perspective of group decision-making, which links 
the diversity of groups with better performance and range of abilities, although at the expense of 
effective processes and equality of participation [15] – a pattern previously observed in MDMs [4-6]. 
Quality improvement efforts, therefore, could consider focusing on the factors identified by our study, 
and assessing them against team processes (e.g. social loafing, blocking, shared information bias), 
quality of decisions made, and patient satisfaction. 
Moreover, our finding of negative surgeon-chair’s input association whereby the surgeons’ inputs into 
case review increase as the chairs’ inputs decrease, is in line with the theory of dual task interference, 
which shows that the competition in dual-task performance is at the detriment of one or both tasks 
[18]. In our sample, chairing was led by the surgical specialty that is also required to provide input 
into case reviews; these are both demanding cognitive tasks. Our study shows that providing both 
types of input at the same time appears to be at the expense of the coordination of the meeting. More 
specifically, when surgical input into case reviews increases, the chair’s input decreases. This is an 
important finding because such internal factors emanating from within the group can affect the way 
the team performs [15]. What is more, this finding can spur strategies for improving MDM practice. 
For instance, assigning a chairing role to a clinically non-contributing individual (e.g. MDT leads from 
other specialties, or cancer managers), trained in team management skills may allow the contributing 
members to focus solely on case reviews and clinical decision-making. Alternatively, rotating the 
chairing duty during a MDM could allow different team members to chair when their direct input is 
not required. Also, experienced specialist nurses could potentially take on this role [32]. 
Further Research  
One question that was directly raised by our findings relates to chairing and dual-task interference. 
Studies should look specifically into the impact of having one of the contributing disciplines in the 
MDT chair the meeting, and test alternative options for meeting leadership that address the burden of 
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the chairing task to the clinical decision making. A second question for future research to address 
relates to the effects of authority gradients on team decision-making process. Authority gradients were 
first defined in aviation where it was observed that differences in seniority and authority impede 
effective communication between pilots and co-pilots [22], and the concept was subsequently 
introduced to medicine in the Institute of Medicine Report, To Err Is Human [21]. While dual-task 
interference is a valid and tested theory that should be investigated further within MDMs, one cannot 
ignore that meetings are attended by more than one person from each specialty. This begs the question 
as to what is the effect of the chair’s authority gradient on information exchange and contributions to 
case reviews from other members of the chair’s discipline. Additionally, this effect should also be 
explored in relation to the other disciplines within the team since nurses, for example, have 
traditionally lower team status. The negative impact of authority gradients on communication between 
healthcare professionals and on patient safety has been well-documented [15,19-22], and classic social 
science research had showed the detrimental effects of blind obedience that such gradients can create 
[23-24]. To illustrate, in a recent interview with MDT members regarding the effectiveness of their 
meetings, one doctor reported: “I am always amazed how very able staff can be so passive” [14]. 
Having an effectively trained leader, and respectful team climate that balance out the authority 
gradients and encourages inputs from all contributing members and disciplines may help improve the 
decision-making process and guard against potential team biases. 
Generalizability 
Although this is a large-scale study for its nature (based on in vivo observations), generalizability of 
our findings may be limited to the most common cancer MDTs within the NHS. Replication and 
assessment of the generalizability of the current findings to other cancer MDTs, in particular the 
lower-frequency cancers, needs to be examined to determine the extent of which they apply to them.  
Conclusion 
As our results demonstrate for the first time, MDT decisions in most common cancers are driven by 
four underlying factors encompassing all participating disciplines and a complete patient profile. It 
seems that all of these elements are necessary for the collective decision-making ability of a team. We 
also demonstrated a negative relationship between chairs’ inputs and their corresponding disciplinary 
clinical input, possibly indicating dual-task interference. Further research could profitably investigate 
how chairing and authority gradients affect team interactions and contributions to case review in 
MDMs with a view to improving service quality and group decision-making in a natural context. 
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Figure 1 Metric for the observation of decision-making used to assess case discussions in cancer 
multidisciplinary team meetings [4] 
Figure 2 Diagram depicting the underlying components of decision-making processes in cancer 
multidisciplinary team meetings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Descriptive data of multidisciplinary team meetings observed 
 
  Meeting Characteristics Outcome 
Cancer Team 
Type of 
Hospital 
No. of meetings 
observed 
No. of core 
members present 
No. of cases 
discussed  
Average no. of cases 
discussed per meeting 
No. of cases with a 
decision reached (%) 
Breast Community 10 13 224 22 203 (91%) 
Colorectal Community 10 11 185 19 161 (87%) 
Lung Teaching 10 13 254 26 218 (86%) 
Urology Community 10 15 382 38 319 (84%) 
Total - 40 52 1045 26 900 (86%) 
OA_Table 1
Table 2 Descriptive data of the scores on the Metric for the Observation of Decision-making in cancer 
Multidisciplinary Teams (MDT-MODe) across cancer teams 
 
Note. N=1045. Scores range from 1 to 5 - higher the scores, better the quality of information and contribution. 
  
Cancer Teams  
  
Lung (n=254) 
 
Breast (n=225) Colorectal (n=185) Urology 
(n=382) 
Overall 
(N=1045) 
MDT-MODe items M (SD) M (SD) M (SD) M (SD) M (SD) 
IN
F
O
R
M
A
T
IO
N
 
  Patient history 3.50 (0.88) 4.43 (0.76) 4.02 (0.84) 3.34 (0.98) 3.73 (0.97) 
  X-Ray 4.69 (0.99) 4.67 (0.81) 4.04 (1.13) 2.59 (1.66) 3.80 (1.58) 
  Pathology 1.62 (1.32) 3.08 (1.69) 2.55 (1.75) 2.73 (1.21) 2.51 (1.44) 
  Psycho-social 2.18 (1.43) 2.44 (1.02) 2.34 (1.34) 1.59 (1.14) 2.05 (1.28) 
  Comorbidity 2.28 (1.33) 2.60 (1.05) 3.06  (1.23) 1.59 (1.14) 2.24 (1.31) 
  Patient view 1.21 (0.74) 2.47 (1.01) 2.45 (1.33) 1.24 (0.82) 1.71 (1.13) 
C
O
N
T
R
IB
U
T
IO
N
 
  Chair 3.88 (1.32) 2.77 (1.54) 3.9 (1) 3.53 (0.68) 3.42 (1.08) 
  Surgeon 1.63 (1.32) 4.23 (1.17) 3.81 (1.02) 4.27 (1.36) 3.54 (1.67) 
  Oncologist 2.16 (1.57) 2.69 (1.57) 3.15 (1.72) 2.09 (1.66) 2.44 (1.67) 
  Nurse 1.95 (1.44) 3.23 (1.00) 3.48 (1.52) 1.18 (0.67) 2.21 (1.48) 
  Radiologist 4.3 (1.11) 4.57 (0.92) 3.81 (1.27) 2.17 (1.76) 3.50 (1.73) 
  Histopathologist 1.69 (1.46) 2.13 (1.47) 2.36 (1.59) 2.07 (1.71) 2.04 (1.59) 
  Coordinator 1.18 (0.63) 1 2.03 (1.24) 1 1.30 (0.94) 
OA_Table 2
Table 3 Rotated factor loadings based on Exploratory Factor Analysis of 13 items of the Metric for the 
Observation of Decision-making in cancer Multidisciplinary Teams (MDT-MODe). 
Note. N=1045. *Item negatively cross-loading.  
 
 Extracted factors 
 1 2 3 4 
MDT-MODe variables Holistic & Clinical 
inputs 
Radiology Pathology Meeting 
Management 
Information quality     
Patient views 0.70 -0.04 -0.06 0.00 
Psychosocial information 0.60 0.01 -0.02 0.34 
Patient history 0.51 0.27 0.09 -0.28 
Comorbidities 0.51 0.16 0.12 0.40 
Radiological information 0.06 0.91 -0.02 -0.12 
Pathological information -0.03 -0.04 0.90 -0.10 
Contribution quality     
Oncologists’ input 0.67 -0.12 -0.19 -0.17 
Nurses’ input 0.65 0.12 -0.05 0.13 
Surgeons’ input 0.43 -0.33 0.19 -0.41* 
Radiologists’ input 0.02 0.93 0.01 -0.11 
Pathologists’ input -0.16 0.04 0.96 0.11 
Coordinator’s input 0.24 -0.15 0.10 0.68 
Chair’s input -0.10 -0.14 -0.07 0.61 
OA_Table 3
Table 4 Logistic regression predicting treatment decision from the extracted factors of the Metric for the Observation of 
Decision-making in cancer Multidisciplinary Teams (MDT-MODe)  
 Unadjusted  Adjusted for tumour type 
  95% CI for OR   95% CI for OR  
Predictor 
B (SE) OR Lower - 
Upper 
Probability 
% 
B (SE) OR Lower - 
Upper 
Probability 
% 
Pathology 0.57 (0.12)* 1.77 1.40 - 2.25 64% 0.59 (0.12)* 1.8 1.42 - 2.28 64% 
Radiology 0.48 (0.10)* 1.62 1.33 - 1.96 62% 0.41 (0.12)* 1.51 1.20 - 1.90 60% 
Holistic & Clinical Inputs 0.47 (0.11)* 1.60 1.28 - 1.99 62% 0.52 (0.12)* 1.68 1.32 - 2.14 63% 
Meeting Management 0.37 (0.10)* 0.70 0.56 - 0.85 41% 0.36 (0.10)** 0.70 0.57 - 0.85 41% 
Constant 2.17 (0.12) 8.77   2.47 (0.32) 0.32   
Note. N = 1045. OR = odds ratio. *p < 0.001. **p < 0.01. -2LL = 734.26. 𝑅2 = 0.18 (Nagelkerke). The predicted variable is treatment 
decision with 0 signifying no decision reached, and 1 decision reached. 
 
OA_Table 4
                          
                                                                                     
 
 Information Contribution OUTCOME 
# Site Point Hx X-ray Path Psy/soc Co-
morbid 
Patient 
view 
Chair Surg    Phys Oncolo Nurse Radiolo Histopath Y/D/N Free text 
1                  
2                  
History 5 Fluent, comprehensive case history. Psycho-
social 
5 Comprehensive first-hand knowledge of patients’ personal circumstances, 
social and psychological issues. 
3 Partial case history. 3 Vague first-hand knowledge, or good second-hand knowledge of personal 
circumstances, social and psychological issues. 
1 No patient case history. 1 No knowledge of personal circumstances, social and psychological issues 
x-ray 5 Radiological images. Co-
morbidity 
5 Comprehensive first-hand knowledge of patients’ past medical history and 
performance status. 
3 Radiological information from a report/ account. 3 Vague first-hand knowledge, or good second-hand knowledge of past 
medical history or performance status. 
1 No provision of radiological information. 1 No knowledge of past medical history or performance status. 
Pathology 5 Histopathological information explained with slides/pictures. Patient’s 
views 
5 Comprehensive first-hand knowledge of patients’ wishes or opinions 
regarding treatment. 
3 Histopathological information from a report/account. 3 Vague first-hand knowledge, or good second-hand knowledge of patient’s 
wishes or opinions regarding treatment. 
1 No provision of Histopathological information. 1 No knowledge of patient’s wishes or opinions regarding treatment. 
Chair 5 Good leadership enhanced team discussion and decision making. Members 5 Clear contribution of speciality. 
 3 Leadership neither enhanced nor impeded team discussion and decision making. 3 Contribution inarticulate or vague. 
1 Poor/inadequate leadership impeded team discussion and decision making. 1 No contribution. 
Point Pre Rx Pre-treatment. Decision Y Clear decision about treatment(s) to be offered. 
Post Rx Post treatment. D Decision to defer to next MDT. 
R Recurrence/ surveillance. N No decision/decision unclear. 
OA_Figure 1 Click here to download OA_Figure Figure 1.docx 
Anatomy of decision-making process in cancer multidisciplinary meetings 
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____________________________________________ 
DATE 
 
(the “Effective Date”), is executed by the corresponding author listed on 
Schedule A (the “Author”) to grant a license to the Medical Research 
Division of Wolters Kluwer Health, Inc.,  a Delaware corporation, having its 
principal place of business at Two Commerce Square, 2001 Market Street, 
Philadelphia, PA 19103 (the “Publisher”, and together with the Author, 
each, a “Party”, and together, the “Parties”). 
 
1. Grant of License 
The Author hereby grants to the Publisher and its affiliates the exclusive, 
worldwide, royalty free, perpetual (for the duration of the applicable 
copyright) right and license to use the Work (as defined on Schedule A) for 
all commercial or educational purposes, including, but not limited to, 
publishing, reproducing, marketing, distributing (themselves and through 
distributors), sublicensing, and selling copies of the Work throughout the 
world for the Term.  If the Author is a United States government employee, 
such license grant shall be limited to the extent the Author is able to grant 
such license. 
 
2. Warranties, Indemnification, and Limitation of Liability 
 
a. The Author represents and warrants to the Publisher that: 
 
(i) the Author has the right and power to enter into this License, to grant 
the rights and licenses granted pursuant to this License, and to perform all 
of the Author’s other obligations contained in this License; 
(ii) the Author has not previously assigned, transferred or otherwise 
encumbered the rights or licenses granted pursuant to this License; and 
that the person executing this License on the Author’s behalf is authorized 
to do so; 
(iii) the Work and the licenses granted herein do not and will not infringe 
upon, violate or misappropriate any intellectual property rights or any 
other proprietary right, contract or other right or interest of any third 
party;  
(iv) if the Work is a multi‐authored Work, the Author has obtained written 
permission from each author of the Work to enter into this License on 
behalf such author, and each such author has read, understands and has 
agreed to the terms of this License;  
(v) the Author has obtained any necessary releases and permissions to 
quote from other sources in the Work and to include any works and 
materials in the Work, including all releases from patients whose names or 
likenesses are submitted as part of the Work; all such releases and 
permissions are in full force and effect, and the Author will promptly 
provide any such release or permission to the Publisher upon request by 
the Publisher; 
(vi) neither the Work nor any content contained in the Work, in whole or in 
part, has been published or is being considered for publication other than 
in the Journal (as defined in Section 3.a.); 
(vii) the Author has disclosed to the Publisher, prior to or simultaneously 
with submission of the Work, all intellectual contributions, technical help, 
financial or material support, and all financial or other relationships that 
may constitute or lead to a conflict of interest; 
(vii) the Work is not subject to any rights of copyright other than the 
copyright of the Author and each other author of the Work; 
(ix) the Work does not and will not violate the publicity or privacy rights of 
any third party, or libel or slander any third party; 
(x) the Work does not and will not contain any scandalous, obscene, or 
negligently prepared information; 
(xi) the Work is not and will not be fraudulent, plagiarized, or incorrectly 
attributed; 
(xii) no aspect of the Author’s personal or professional circumstances 
currently, or in the past 12 months, causes the Author to have a conflict of 
interest with respect to the Work; 
(xiii) neither the Author, nor any member of the Author’s immediate 
family, nor any individual or entity with whom or which the Author has or 
has had a significant working relationship has received anything of value 
from a commercial party related directly or indirectly to the subject of the 
Work; and 
(xiv) the Author has read and understands the statements on each of 
Schedule B and Schedule C and has completed both Schedule B and 
Schedule C in their entirety. 
 
b. The Author hereby indemnifies the Publisher and its directors, officers, 
employees, agents, and representatives and agrees to defend and hold 
them harmless from and against any and all liability, damage, loss, costs or 
expenses (including reasonable attorney’s fees and costs of settlement) 
incurred by any such party arising out of, or relating to any 
misrepresentation in, or breach or alleged breach of the Author’s 
representations or warranties in this License.  If the Author fails to 
promptly or diligently pursue any defense of any indemnified party, the 
indemnified parties, or any of them, may assume such defense at the 
Author’s expense.  The obligations of this indemnification will survive any 
termination or expiration of this License. 
 
3. Creative Commons License  
   
a. If the Author has not selected either “Research Councils UK (RCUK)” or  
“Wellcome Trust” in Item 1 of Schedule B, the following shall apply:   
 
The Author acknowledges and agrees that the Work will be published by 
the Publisher in Medicine (the “Journal”) and made freely available to 
users under the terms of one of the following Creative Commons Licenses, 
which license will be selected by the Author pursuant to Schedule B: 
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(i) Creative Commons Attribution 4.0 International Public License, as 
currently displayed at 
http://creativecommons.org/licenses/by/4.0/legalcode (the “CC BY”).  The 
Author acknowledges and agrees that the Publisher is the exclusive 
“Licensor”, as defined in the CC BY, of the Work and that the Publisher may 
make the Work freely available to all users under the terms of the CC BY. 
(ii) Creative Commons Attribution‐NoDerivatives 4.0 International Public 
License, as currently displayed at http://creativecommons.org/licenses/by‐
nd/4.0/legalcode (the “CC BY‐ND”).  The Author acknowledges and agrees 
that the Publisher is the exclusive “Licensor”, as defined in the CC BY‐ND, 
of the Work and that the Publisher may make the Work freely available to 
all users under the terms of the CC BY‐ND. 
(iii) Creative Commons Attribution‐ShareAlike 4.0 International Public 
License, as currently displayed at http://creativecommons.org/licenses/by‐
sa/4.0/legalcode (the “CC BY‐SA”).  The Author acknowledges and agrees 
that the Publisher is the exclusive “Licensor”, as defined in the CC BY‐SA, of 
the Work and that the Publisher may make the Work freely available to all 
users under the terms of the CC BY‐SA. 
(iv) Creative Commons Attribution‐NonCommercial 4.0 International Public 
License, as currently displayed at http://creativecommons.org/licenses/by‐
nc/4.0/legalcode (the “CC BY‐NC”).  The Author acknowledges and agrees 
that the Publisher is the exclusive “Licensor”, as defined in the CC BY‐NC, 
of the Work and that the Publisher may make the Work freely available to 
all users under the terms of the CC BY‐NC. 
(v) Creative Commons Attribution‐NonCommercial‐ShareAlike 4.0 
International Public License, as currently displayed at 
http://creativecommons.org/licenses/by‐nc‐sa/4.0/legalcode (the “CC BY‐
NC‐SA”).  The Author acknowledges and agrees that the Publisher is the 
exclusive “Licensor”, as defined in the CC BY‐NC‐SA, of the Work and that 
the Publisher may make the Work freely available to all users under the 
terms of the CC BY‐NC‐SA. 
(vi) Creative Commons Attribution‐NonCommercial‐NoDerivatives 4.0 
International Public License, as currently displayed at 
http://creativecommons.org/licenses/by‐nc‐nd/4.0/legalcode (the “CC BY‐
NC‐ND”).  The Author acknowledges and agrees that the Publisher is the 
exclusive “Licensor”, as defined in the CC BY‐NC‐ND, of the Work and that 
the Publisher may make the Work freely available to all users under the 
terms of the CC BY‐NC‐ND. 
   
b. If the Author has selected either “Research Councils UK (RCUK)” or 
“Wellcome Trust” in Item 1 of Schedule B, the following shall apply: 
 
The Author acknowledges and agrees that the Work will be published by 
the Publisher in Medicine (the “Journal”) and made freely available to 
users under the terms of the Creative Commons Attribution 4.0 
International Public License, as currently displayed at 
http://creativecommons.org/licenses/by/4.0/legalcode (the “CC BY”).  The 
Author acknowledges and agrees that the Publisher is the exclusive 
“Licensor”, as defined in the CC BY, of the Work and that the Publisher may 
make the Work freely available to all users under the terms of the CC BY. 
 
4. Royalties 
   
The Author acknowledges and agrees that this License entitles the Author 
to no royalties or fees.  To the maximum extent permitted by law, the 
Author waives any and all rights the Author may have to collect royalties or 
other fees in relation to the Work or in respect of any use of the Work by 
the Publisher or its sublicensees. 
 
5. Miscellaneous 
 
a. Assignment. This License may not be assigned or transferred, in whole or 
in part, by the Author.  The Publisher may freely assign this License.  This 
License will be binding upon and inure to the benefit of the Parties hereto 
and their respective successors and permitted assigns. 
b. Execution. Facsimile or Portable Document Format (PDF) signatures will 
be deemed original signatures for purposes of this License. 
c. Entire Agreement; Amendment. This License sets forth the entire 
agreement of the Parties on the subject hereof and supersedes all previous 
or contemporaneous oral or written representations or agreements 
relating to the rights and duties provided herein, and may not be modified 
or amended except by written agreement of the Publisher. 
d. Governing Law. This License shall be governed in all respects according 
to the laws of the State of New York without giving effect to the principles 
of conflict of law thereof. 
e. Headings. All headings are for reference purposes only and shall not 
affect the meaning or interpretation of any provision hereof. 
g. Severability. If any provision of this License is held to be illegal, invalid, 
or unenforceable under the present or future laws, then such provision 
shall be revised by a court of competent jurisdiction to be enforceable if 
permitted under applicable law, and otherwise shall be fully severable.  In 
any event, this License shall be construed and enforced as if such illegal, 
invalid, or unenforceable provision had never comprised a part of this 
License, and the remaining provisions of this License shall remain in full 
force and effect and shall not be affected by the illegal, invalid, or 
unenforceable provision or by its severance from this License. 
h. Status of the Parties. The Parties are independent contractors.  Nothing 
in this License is intended to or shall be construed to constitute or 
establish any agency, joint venture, partnership or fiduciary relationship 
between the Parties, and neither Party has the right or authority to bind 
the other Party nor shall either Party be responsible for the acts or 
omissions of the other Party. 
i. Waiver; Amendment.  The waiver by the Publisher of or the failure by the 
Publisher to claim a breach of any provision of this License shall not be, or 
be held to be, a waiver of any subsequent breach or affect in any way the 
further effectiveness of any such provision.  No term or condition of this 
License may be waived except by an agreement by the Publisher in writing. 
j. Waiver of Jury Trial.  THE AUTHOR WAIVES THE AUTHOR’S RIGHT TO A 
JURY TRIAL IN CONNECTION WITH ANY DISPUTE OR LEGAL PROCEEDING 
ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF.
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SCHEDULE A 
 
The Author must complete this Schedule A in its entirety. The Publisher is unable to publish the Work unless this Schedule A 
is completely filled out. 
 
 
______________________________________________________________________ 
Article Title (the “Work”) 
 
 
______________________________________________________________________ 
Corresponding Author Name (the “Author”) 
 
 
______________________________________________________________________ 
Copyright Owner’s Name 
 
 
______________________________________________________________________ 
Manuscript Number (Optional) 
 
 
 
SCHEDULE B 
 
GOVERNMENT EMPLOYEES 
  
If the Work or a portion of it has been created in the course of any author's employment by the United States Government, 
check the "Government" box.  
A work prepared by a government employee as part of his or her official duties is called a "work of the U.S. Government" and is not 
subject to copyright. If it is not prepared as part of the employee's official duties, it may be subject to copyright.  
 
If “Government” is chosen, please skip to Schedule C and do not choose a Copyright Clearance License. The work will be 
published with “Written work prepared by employees of the Federal Government as part of their official duties is, under 
the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the 
United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal 
Government.” 
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CREATIVE COMMONS LICENSE 
 
Please select the Creative Commons License pursuant to which the Publisher will  license the Work (a description of each 
license, and the license terms, can be reviewed at http://www.creativecommons.org/licenses): 
Select one from the list below: 
 
Attribution  CC BY.  Creative  Commons  describes  this  license  as  follows:    “This  license  lets  others  distribute,  remix, 
tweak, and build upon your work, even commercially, as  long as they credit you for the original creation. This  is the 
most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials.” 
Attribution‐NoDerivs  CC  BY‐ND.  Creative  Commons  describes  this  license  as  follows:  “This  license  allows  for 
redistribution, commercial and non‐commercial, as  long as  it  is passed along unchanged and  in whole, with credit to 
you.” 
Attribution‐ShareAlike CC BY‐SA. Creative Commons describes this  license as follows: “This  license  lets others remix, 
tweak,  and build upon  your work  even  for  commercial purposes,  as  long  as  they  credit  you  and  license  their new 
creations under the identical terms. This license is often compared to ‘copyleft’ free and open source software licenses. 
All new works based on yours will carry the same license, so any derivatives will also allow commercial use. This is the 
license used by Wikipedia,  and  is  recommended  for materials  that would benefit  from  incorporating  content  from 
Wikipedia and similarly licensed projects.” 
Attribution‐NonCommercial CC BY‐NC. Creative Commons describes  this  license as  follows: “This  license  lets others 
remix, tweak, and build upon your work non‐commercially, and although their new works must also acknowledge you 
and be non‐commercial, they don’t have to license their derivative works on the same terms.” 
Attribution‐NonCommercial‐ShareAlike  CC  BY‐NC‐SA.  Creative  Commons  describes  this  license  as  follows:  “This 
license  lets others remix, tweak, and build upon your work non‐commercially, as  long as they credit you and  license 
their new creations under the identical terms.” 
Attribution‐NonCommercial‐NoDerivs CC BY‐NC‐ND. Creative Commons describes this license as follows:  “This license 
is  the most  restrictive of our  six main  licenses, only  allowing others  to download  your works  and  share  them with 
others as long as they credit you, but they can’t change them in any way or use them commercially.” 
Medicine – License to Publish  5
SCHEDULE C 
 
The Author must complete this Schedule C in its entirety. The Publisher is unable to publish the Work unless this Schedule C 
is completely filled out.  
 
Generic and Trade Names  
 
Articles  must  give  a  balanced  view  of  therapeutic  options.  Authors’  use  of  generic  names  will  contribute  to  this 
impartiality.  If  trade names  are used,  those of  several  companies  should be used  rather  than only  that of  a  single 
support company.  It is each author's responsibility to disclose in the Work any commercial support related directly or 
indirectly to the subject of the Work. It is also each author's responsibility to include the Food and Drug Administration 
clearance  status  of  any  device  or  drug  requiring  FDA  approval  discussed  or  described  in  their  presentation  or  to 
describe the lack of FDA clearance for any “off label” uses discussed. 
 
Please check box to affirm the preceding statement. 
 
 
Unlabeled Uses of Products  
When  an  unlabeled  use  of  a  commercial  product,  or  an  investigational  use  not  yet  approved  for  any  purpose  is 
discussed during an educational activity, the presenter is required to disclose that the product is not labeled for the use 
under discussion or that the product is still investigational.  
 
Discussion of unlabeled uses: 
 
The Work does not discuss unlabeled uses of products  
 
The Work discusses unlabeled uses of products. (If this option is selected, please provide in the space provided below 
a detailed description of the unlabeled uses of products discussed in the Work) 
 
  Description of unlabeled uses of products discussed in the Work: 
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SIGNATURE PAGE 
 
IN WITNESS WHEREOF, the Author has executed this License, effective as of the Effective Date. 
 
 
______________________________________________________________________ 
PRINT NAME 
 
 
 
 
______________________________________________________________________ 
SIGNATURE 
 
Important Note: Once you electronically sign this form, you will not be able to make any additional changes to it. 
To electronically sign this form, click the signature field above and provide the information requested in the dialog boxes. 
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